MarketCap
Facebook
X
TelegramMisonix, Inc. Revenue 2011-2026 | MSON
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Misonix, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 62.5 M | 38.8 M | 36.7 M | 27.3 M | 23.1 M | 22.2 M | 17.1 M | 14.8 M | 15.7 M | 14.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 62.5 M | 14.4 M | 27.3 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
3.37 B | $ 39.27 | -1.36 % | $ 5.85 K | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
443 M | $ 7.82 | 4.13 % | $ 561 M |  Israel |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 9.4 | -2.49 % | $ 1.27 B | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.99 | -2.68 % | $ 149 M |  France |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 43.41 | -5.2 % | $ 1.35 B | USA |
 |
Electromed
ELMD
|
64 M | $ 23.98 | -0.5 % | $ 203 M | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
225 M | $ 29.83 | -2.68 % | $ 1.37 B | USA |
 |
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.17 | -3.35 % | $ 110 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
FONAR Corporation
FONR
|
97.6 M | $ 18.5 | -0.32 % | $ 121 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Accuray Incorporated
ARAY
|
459 M | $ 0.53 | -4.57 % | $ 54.5 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.8 | 6.81 % | $ 43.5 M | USA |
 |
Align Technology
ALGN
|
4 B | $ 182.64 | -3.38 % | $ 13.7 B | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Inari Medical
NARI
|
383 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
82.1 M | $ 3.68 | -4.42 % | $ 779 M | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
44.3 B | $ 113.61 | -0.45 % | $ 198 B | USA |
 |
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 73.85 | -3.11 % | $ 109 B | USA |
 |
Helius Medical Technologies
HSDT
|
644 K | $ 1.98 | -6.6 % | $ 1.2 M | USA |
 |
Alphatec Holdings
ATEC
|
764 M | $ 13.02 | -3.34 % | $ 1.95 B | USA |
 |
InMode Ltd.
INMD
|
358 M | $ 13.6 | -0.29 % | $ 879 M | Israel |
 |
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 85.28 | -2.18 % | $ 49.9 B | USA |
 |
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.43 | 1.42 % | $ 23.1 M | USA |
 |
IRadimed Corporation
IRMD
|
73.2 M | $ 104.29 | 0.53 % | $ 1.32 B | USA |